MCM
KZR

Mendel Capital Management’s Kezar Life Sciences KZR Stock Holding History

Mendel Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,273
Closed -$213K – 70
2021
Q4 		$213K Buy
+1,273
New +$144K 0.2% 69

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Mendel Capital Management's KZR Position: Q1 2022 in Review

Mendel Capital Management sold out of Kezar Life Sciences (KZR) in Q1 2022, closing a stake of 1,273 shares — an estimated $213K sold.

Mendel Capital Management first reported a position in KZR in Q4 2021 and held it in 1 quarter. The position peaked at $213K in Q4 2021. 123 funds tracked by Wall St. Rank hold KZR as of Q1 2022.

  • Mendel Capital Management reported no remaining Kezar Life Sciences position as of Q1 2022 after selling out during the quarter.
  • Mendel Capital Management sold 1,273 Kezar Life Sciences shares in Q1 2022, an estimated $213K.
  • Mendel Capital Management first reported a position in Kezar Life Sciences in Q4 2021 and held it in 1 quarter.
  • Mendel Capital Management's Kezar Life Sciences position peaked at $213K in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2022.

Based on Mendel Capital Management's 13F filing for Q1 2022, filed 2 May 2022.